Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.

Studied

Tirzepatide for high blood glucose that developed during pasireotide treatment for a hormone-producing pituitary tumor.

Who / model

One 48-year-old woman treated with pasireotide after pituitary surgery. Sitagliptin and oral semaglutide had not adequately controlled her glucose. Follow-up duration is not given in the abstract.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

After switching to tirzepatide, HbA1c, a measure of average blood sugar, fell from 7.7% to 6.3%, and random glucose measurements also improved.

Limits

A single case cannot establish comparative effectiveness. The authors call for studies comparing the result with intensified GLP-1 therapy.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary